SCHEMBL4055727

SCHEMBL4055727

C(=Cc1cnc2nc(C=Cc3ccccc3)[nH]c2c1)c1ccccc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 5/20 0.55
RAB9A P51151 4/20 0.55
KDM4E B2RXH2 3/20 0.55
ALDH1A1 P00352 3/20 0.55
SMN1; SMN2 Q16637 3/20 0.55
MEN1 O00255 2/20 0.55
PKM P14618 2/20 0.55
HPGD P15428 2/20 0.55
KMT2A Q03164 2/20 0.55
HSP90AA1 P07900 1/20 0.55
MAPK1 P28482 2/20 0.50
MAPT P10636 3/20 0.49
ATM Q13315 1/20 0.49
PDGFRB P09619 2/20 0.49
PDGFRA P16234 2/20 0.49
IP6K1 Q92551 1/20 0.47
TUBB4A P04350 7/20 0.44
TUBB P07437 7/20 0.44
TUBA3C P0DPH7 7/20 0.44
TUBA1B P68363 7/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4055724 1.00 NPC1 (0.55) NPC1RAB9AKDM4EALDH1A1SMN1; SMN2
SCHEMBL4056638 0.87 NPC1 (0.51) NPC1RAB9AKDM4EALDH1A1SMN1; SMN2
SCHEMBL4055882 0.87 MAPT (0.62) NPC1RAB9AKDM4EALDH1A1SMN1; SMN2
SCHEMBL4056642 0.87 NPC1 (0.51) NPC1RAB9AKDM4EALDH1A1SMN1; SMN2
SCHEMBL4055881 0.87 MAPT (0.62) NPC1RAB9AKDM4EALDH1A1SMN1; SMN2
SCHEMBL4060113 0.80 NPC1 (0.45) NPC1RAB9AKDM4EALDH1A1SMN1; SMN2
SCHEMBL4060105 0.80 NPC1 (0.45) NPC1RAB9AKDM4EALDH1A1SMN1; SMN2
SCHEMBL4059729 0.79 NPC1 (0.44) NPC1RAB9AKDM4EALDH1A1SMN1; SMN2
SCHEMBL4059720 0.79 NPC1 (0.44) NPC1RAB9AKDM4EALDH1A1SMN1; SMN2
SCHEMBL4056022 0.79 NPC1 (0.44) NPC1RAB9AKDM4EALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7622479-B2 Bicyclic derivative, its production and use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-11-24 US disclosed
US-20050101647-A1 Bicyclic derivative, its production and use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2005-05-12 US disclosed
EP-1460067-A1 BICYCLIC DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND USE Takeda Chemical Industries, Ltd. (JP) 2004-09-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050101647-A1 Bicyclic derivative, its production and use ABL1, SRC, PTK2B NPC1 4740/4885RAB9A 1184/4885KDM4E 496/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.